clinical trial · NCT05585398
A Study to Evaluate the Distribution of Botulinum Neurotoxin Type A Administered as Intradermal Injections, Comparing Different Doses, Concentrations, and Delivery Methods
N/A, as no Specific Medical Condition Will be TreatedIncobotulinumtoxinA
brief summary
The purpose of this study is to evaluate the distribution of IncobotulinumtoxinA (Xeomin) in healthy subjects at different volumes, concentrations and doses when administered intradermally and subcutaneously using different delivery methods (conventional needle and microneedles).
started
Oct 19, 2022
primary completion
Feb 24, 2023
completion
Apr 13, 2023
last updated
Jun 22, 2023
official title
A Phase 1 Single-center Study to Evaluate the Distribution of NT 201 Administered as Intradermal Injections, Comparing Different Doses, Concentrations, and Delivery Methods
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol